Glenmark Life Sciences, a subsidiary of Nirma Limited, a diversified conglomerate with interest in consumer products, cement, chemicals and pharmaceuticals. It is a leading developer and manufacturer of select, high-value, non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas. The company further operates in Contract Development and manufacturing operations to offer services to specialty Pharmaceutical companies.
Financial Results:
Alivus Life Sciences Ltd reported Revenues for Q4FY25 of ₹1,056.00 Crores up from ₹944.00 Crore year on year, a rise of 11.86%.
Total Expenses for Q4FY25 of ₹1,007.00 Crores up from ₹987.00 Crores year on year, a rise of 2.03%.
Consolidated Net Profit of ₹150.00 Crores from -₹39.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹9.38, from -₹2.89 in the same quarter of the previous year.